| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 4.008 | 13.299 | 13.329 | 17.856 | 27.031 | 50.962 | 52.520 | 67.260 | 46.829 |
| Total Income - EUR | - | 4.621 | 13.985 | 13.329 | 17.856 | 27.031 | 50.962 | 52.520 | 67.260 | 46.829 |
| Total Expenses - EUR | - | 5.064 | 5.914 | 5.579 | 6.313 | 6.214 | 6.208 | 6.583 | 8.242 | 9.956 |
| Gross Profit/Loss - EUR | - | -443 | 8.071 | 7.749 | 11.543 | 20.817 | 44.754 | 45.937 | 59.017 | 36.872 |
| Net Profit/Loss - EUR | - | -524 | 7.652 | 7.616 | 11.364 | 20.565 | 44.255 | 45.422 | 58.358 | 35.496 |
| Employees | - | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Endocrinomedical S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 293 | 22 |
| Current Assets | - | 843 | 7.605 | 7.974 | 14.833 | 21.220 | 45.091 | 47.865 | 59.446 | 36.909 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 0 | 2.080 | 322 | 1.370 | 2.100 | 10.820 | 36.238 | 12.211 | 6.272 |
| Cash | - | 843 | 5.525 | 7.651 | 13.463 | 19.120 | 34.271 | 11.627 | 47.235 | 30.636 |
| Shareholders Funds | - | -479 | 7.181 | 7.668 | 11.415 | 20.615 | 44.304 | 45.471 | 58.407 | 35.544 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 1.322 | 424 | 306 | 3.418 | 606 | 788 | 2.394 | 1.332 | 1.387 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Endocrinomedical S.r.l.